Special Issue "Anticoagulants"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (20 December 2011)

Special Issue Editor

Guest Editor
Prof. Dr. Sam Schulman
Department of Medicine, McMaster University, Hamilton, ON, Canada
Website: http://www.fhs.mcmaster.ca/medicine/hematology/faculty_member_schulman.htm
E-Mail: schulms@mcmaster.ca

Special Issue Information

Dear Colleagues,

After 60 years with warfarin and heparins as the only commonly used anticoagulants, the past 20 years have provided an impressive row of new agents. Low-molecular-weight heparins resulted in the first change of paradigm by enabling outpatient care of many patients with venous thromboembolism. The next shift should be the obviated need for routine laboratory monitoring and frequent dose adjustments of the oral anticoagulant. The purpose of this special issue is to assess the current status of the array of new anticoagulants at advanced stages of clinical trials. There are, however, still hurdles on the way, for example the question of reversal of such agents in emergency situations and how the higher cost of any new drug can be justified to the payers in view of the very inexpensive vitamin K antagonists, keeping in mind the considerable management costs associated with the latter.

Prof. Sam Schulman, MD
Guest Editor

Keywords

  • dabigatran
  • rivaroxaban
  • apixaban
  • betrixaban
  • edoxaban
  • otamixaban
  • AVE5026
  • bleeding
  • health economy

Published Papers (6 papers)

by  and
Pharmaceuticals 2010, 3(12), 3543-3569; doi:10.3390/ph3123543
Received: 7 October 2010; in revised form: 7 December 2010 / Accepted: 9 December 2010 / Published: 10 December 2010
Show/Hide Abstract | Cited by 4 | PDF Full-text (240 KB) | HTML Full-text | XML Full-text

by
Pharmaceuticals 2011, 4(11), 1475-1487; doi:10.3390/ph4111475
Received: 13 September 2011; in revised form: 22 October 2011 / Accepted: 24 October 2011 / Published: 7 November 2011
Show/Hide Abstract | PDF Full-text (205 KB) | HTML Full-text | XML Full-text

by  and
Pharmaceuticals 2012, 5(2), 155-168; doi:10.3390/ph5020155
Received: 26 December 2011; in revised form: 1 February 2012 / Accepted: 1 February 2012 / Published: 3 February 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (370 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2012, 5(3), 279-296; doi:10.3390/ph5030279
Received: 20 December 2011; in revised form: 18 January 2012 / Accepted: 20 February 2012 / Published: 24 February 2012
Show/Hide Abstract | Cited by 6 | PDF Full-text (823 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2012, 5(4), 384-397; doi:10.3390/ph5040384
Received: 15 March 2012; in revised form: 16 March 2012 / Accepted: 28 March 2012 / Published: 5 April 2012
Show/Hide Abstract | PDF Full-text (139 KB) | HTML Full-text | XML Full-text

by  and
Pharmaceuticals 2012, 5(5), 469-480; doi:10.3390/ph5050469
Received: 29 March 2012; in revised form: 28 April 2012 / Accepted: 28 April 2012 / Published: 4 May 2012
Show/Hide Abstract | PDF Full-text (198 KB) | HTML Full-text | XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert